Role of mutagenicity in asbestos fiber-induced carcinogenicity and other diseases, J Toxicol Environ Health B Crit Rev, vol.14, pp.179-245, 2011. ,
Molecular changes in mesothelioma with an impact on prognosis and treatment, Arch Pathol Lab Med, vol.136, pp.277-93, 2012. ,
URL : https://hal.archives-ouvertes.fr/inserm-02478588
Causes and pathophysiology of malignant pleural mesothelioma, Lung Cancer Management, vol.4, p.10, 2015. ,
URL : https://hal.archives-ouvertes.fr/inserm-02483449
Whole-exome sequencing reveals frequent genetic alterations in BAP1, NF2, CDKN2A, and CUL1 in malignant pleural mesothelioma, Cancer Res, vol.75, pp.264-273, 2015. ,
Gender-Specific Molecular and Clinical Features underlie Malignant Pleural Mesothelioma, Cancer Res, 2015. ,
Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations, Nat Genet, vol.48, pp.407-423, 2016. ,
Overexpression and promoter mutation of the TERT gene in malignant pleural mesothelioma, Oncogene, vol.33, pp.3748-52, 2014. ,
URL : https://hal.archives-ouvertes.fr/inserm-02478602
Molecular Classification of Malignant Pleural Mesothelioma: Identification of a Poor Prognosis Subgroup Linked to the Epithelial-to-Mesenchymal Transition, Clin Cancer Res, vol.20, pp.1323-1357, 2014. ,
URL : https://hal.archives-ouvertes.fr/inserm-02478599
Control of proliferation and cancer growth by the Hippo signaling pathway, Mol Cancer Res, 2015. ,
YAP1 is involved in mesothelioma development and negatively regulated by Merlin through phosphorylation, Carcinogenesis, vol.29, pp.2139-2185, 2008. ,
YAP induces malignant mesothelioma cell proliferation by upregulating transcription of cell cyclepromoting genes, Oncogene, vol.31, pp.5117-5139, 2012. ,
Hippo/YAP pathway for targeted therapy, Transl Lung Cancer Res, vol.3, pp.75-83, 2014. ,
LATS2 is a tumor suppressor gene of malignant mesothelioma, Cancer Res, vol.71, pp.873-83, 2011. ,
The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma, Nat Genet, vol.43, pp.668-72, 2011. ,
Syntenic Relationships between Genomic Profiles of Fiber-Induced Murine and Human Malignant Mesothelioma, Am J Pathol, vol.178, pp.881-94, 2011. ,
URL : https://hal.archives-ouvertes.fr/inserm-00531343
Differential mutation profiles and similar intronic TP53 polymorphisms in asbestos-related lung cancer and pleural mesothelioma, Mutagenesis, vol.28, pp.323-354, 2013. ,
URL : https://hal.archives-ouvertes.fr/inserm-02478590
ATM has a major role in the double-strand break repair pathway dysregulation in sporadic breast carcinomas and is an independent prognostic marker at both mRNA and protein levels, Br J Cancer, vol.112, pp.1059-66, 2015. ,
NormaCurve: a SuperCurve-based method that simultaneously quantifies and normalizes reverse phase protein array data, PLoS One, vol.7, p.38686, 2012. ,
limma powers differential expression analyses for RNA-sequencing and microarray studies, Nucleic Acids Res, vol.43, p.47, 2015. ,
Malignant Pleural Mesothelioma: Present Status and Future Directions: Bentham eBooks, pp.169-92, 2016. ,
Hippo pathway gene mutations in malignant mesothelioma: revealed by RNA and targeted exon sequencing, J Thorac Oncol, vol.10, pp.844-51, 2015. ,
A network of cancer genes with co-occurring and anti-co-occurring mutations, PLoS One, vol.5, 2010. ,
Functional inactivation of NF2/merlin in human mesothelioma, Lung Cancer, vol.64, pp.140-147, 2009. ,
Hemizygosity of Nf2 is associated with increased susceptibility to asbestos-induced peritoneal tumours, Oncogene, vol.22, pp.3799-805, 2003. ,
URL : https://hal.archives-ouvertes.fr/hal-01928405
A conditional mouse model for malignant mesothelioma, Cancer Cell, vol.13, pp.261-71, 2008. ,
Reexpression of the tumor suppressor NF2/merlin inhibits invasiveness in mesothelioma cells and negatively regulates FAK, Oncogene, vol.25, pp.5960-5968, 2006. ,
The NF2 tumor suppressor gene product, merlin, inhibits cell proliferation and cell cycle progression by repressing cyclin D1 expression, Mol Cell Biol, vol.25, pp.2384-94, 2005. ,
Overexpression of renal tumor antigen is associated with tumor invasion and poor prognosis of hepatocellular carcinoma, Ann Surg Oncol, vol.19, issue.3, pp.404-415, 2012. ,
Heterogeneous expression of the tumor-associated antigens RAGE-1, PRAME, and glycoprotein 75 in human renal cell carcinoma: candidates for T-cell-based immunotherapies?, Cancer Res, vol.58, pp.4090-4095, 1998. ,
Cancer testis antigens expression in mesothelioma: role of DNA methylation and bioimmunotherapeutic implications, Br J Cancer, vol.86, pp.979-82, 2002. ,
TEAD mediates YAP-dependent gene induction and growth control, Genes Dev, vol.22, pp.1962-71, 2008. ,
YAP1 Exerts Its Transcriptional Control via TEAD-Mediated Activation of Enhancers, PLoS Genet, vol.11, p.1005465, 2015. ,
Genetic and pharmacological disruption of the TEAD-YAP complex suppresses the oncogenic activity of YAP, Genes Dev, vol.26, pp.1300-1305, 2012. ,
LIM-domain protein AJUBA suppresses malignant mesothelioma cell proliferation via Hippo signaling cascade, Oncogene, vol.34, pp.73-83, 2015. ,
Loss of the tumor suppressor gene NF2, encoding merlin, constitutively activates integrin-dependent mTORC1 signaling, Mol Cell Biol, vol.29, pp.4235-4284, 2009. ,
FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression, Science, vol.321, pp.1499-502, 2008. ,
Lysosomal pH Plays a Key Role in Regulation of mTOR Activity in Osteoclasts, J Cell Biochem, vol.117, pp.413-438, 2016. ,
SWOG S0722: phase II study of mTOR inhibitor everolimus (RAD001) in advanced malignant pleural mesothelioma (MPM), J Thorac Oncol, vol.10, pp.387-91, 2015. ,
Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer, J Clin Invest, vol.118, pp.3065-74, 2008. ,
Mammalian target of rapamycin contributes to the acquired apoptotic resistance of human mesothelioma multicellular spheroids, J Biol Chem, vol.283, pp.13021-13051, 2008. ,
Multipoint targeting of the PI3K/mTOR pathway in mesothelioma, Br J Cancer, vol.110, pp.2479-88, 2014. ,
Inhibition of autophagy sensitizes malignant pleural mesothelioma cells to dual PI3K/mTOR inhibitors, Cell Death Dis, vol.6, p.1757, 2015. ,
Discovery of the highly potent PI3K/mTOR dual inhibitor PF-04691502 through structure based drug design, Med Chem Commun, vol.1, pp.139-183, 2010. ,
PF-04691502 triggers cell cycle arrest, apoptosis and inhibits the angiogenesis in hepatocellular carcinoma cells, Toxicol Lett, vol.220, pp.150-156, 2013. ,
Phase I study of PF-04691502, a small-molecule, oral, dual inhibitor of PI3K and mTOR, in patients with advanced cancer, Invest New Drugs, vol.32, pp.510-517, 2014. ,
A randomized phase II non-comparative study of PF-04691502 and gedatolisib (PF-05212384) in patients with recurrent endometrial cancer, Gynecol Oncol, 2016. ,